According to The New York Times, a drug that’s in a phase-three trial, the results of which were published in The New England Journal of Medicine, helped kids with severe peanut allergies withstand the equivalent of two peanut kernels while avoiding the crazy-severe side effects.
The drug, called AR101, developed and tested by Aimmune Therapeutics, helps build immunity to the nut by administering a small dose each day. This builds tolerance over time, a common strategy for preventing new nut allergies and helping existing ones withstand exposure.
Wonderful news for the nearly 15 million Americans with allergies (yes, including your co-worker who always asks what’s in the homemade cookies). Fingers crossed that it’s out of the trial phase soon.